Dogecoin Cash, Inc. ($CBDS) Expands into Meme Coin Market with Formation of MEME COINS Inc.
By Dr. Matthew Watson
MESQUITE, NV, March 10, 2025 (GLOBE NEWSWIRE) -- March 10, 2025 – Mesquite, NV – Dogecoin Cash, Inc. ($CBDS), a publicly traded leader in blockchain innovation, is excited to announce its strategic expansion into the rapidly growing meme coin market. Inspired by the meteoric success of recent meme coins launched by high-profile figures like Donald Trump and Melania Trump, $CBDS is forming a new subsidiary, MEME COINS Inc., to drive acquisitions and investments in the space while protecting shareholder equity.Riding the Wave of Cultural RelevanceMeme coins have become a powerful cultural and financial force, with billions of dollars traded daily. Their unique blend of viral marketing, community-driven support, and speculative appeal has attracted both retail and institutional investors. The success of high-profile meme coins underscores the immense potential for innovation in this space.“As we’ve seen with recent launches, meme coins have evolved into a mainstream asset class, engaging investors in ways traditional cryptocurrencies have not. Through the formation of MEME COINS Inc. we are structuring our expansion to maximize opportunities while minimizing dilution for CBDS shareholders,” said David Tobias, CEO of Dogecoin Cash, Inc.Why the Meme Coin Market?The exponential growth of the meme coin market is driven by:Global Appeal – Meme coins transcend borders and demographics, fueled by internet culture. Community Power – Strong online communities drive engagement and long-term value. New Revenue Streams– Meme coins can integrate into broader ecosystems, creating opportunities for DeFi, NFTs, and gaming. Cultural Influence – Endorsements from public figures and brands amplify adoption and legitimacy. CBDS and MEME COINS Inc. will build a diversified portfolio of meme coin assets and projects that combine cultural relevance with sound financial utility.Formation of MEME COINS Inc. and Strategic Acquisition PlanTo execute this vision while avoiding dilution to $CBDS shareholders, the company is launching a wholly owned subsidiary, MEME COINS Inc., which will focus on:Acquiring Established Meme Coins – Targeting assets like Dogecoin and other high-potential meme coins. Issuing Preferred Shares – MEME COINS Inc. will raise funds through preferred shares rather than issuing common stock, ensuring that CBDS shareholders maintain their equity positions. Strategic Partnerships & Investments – Investing in new and existing meme coin projects with strong community engagement and financial potential. This approach allows $CBDS to capitalize on the meme coin boom while preserving its equity structure and protecting long-term investor value.The $CBDS Business PlanDogecoin Cash, Inc. and MEME COINS Inc. will execute a three-pronged strategy:1. Development of Proprietary Meme Coins – Launching branded meme coins with real-world applications, such as charity contributions, gamification, and exclusive content access. 2. Partnerships with Influencers – Collaborating with cultural icons and internet influencers to drive viral marketing campaigns. 3. Community-First Ecosystem – Creating a platform where meme coin communities can trade, engage, and participate in decentralized governance. Commitment to Sustainable GrowthDogecoin Cash, Inc. is uniquely positioned to add legitimacy and long-term value to the meme coin market by emphasizing transparency, security, and scalability. Through responsible development, strategic acquisitions, and financial innovation, the company aims to redefine how meme coins are perceived and utilized.Looking AheadDogecoin Cash, Inc. invites investors, developers, and the broader cryptocurrency community to join us in this bold venture. Through MEME COINS Inc., we are not only embracing the future of digital finance but also ensuring that our investors benefit from this explosive market with minimal dilution.For more information about Dogecoin Cash, Inc. and MEME COINS Inc. visit www.cbds.com.
Link:
Dogecoin Cash, Inc. ($CBDS) Expands into Meme Coin Market with Formation of MEME COINS Inc.
- Leading Independent Proxy Advisor Glass Lewis Recommends Shareholders Vote the GREEN proxy FOR ALL MediPharm Director Nominees - June 16th, 2025
- RAPT Therapeutics Announces Effective Date for 1-for-8 Reverse Stock Split - June 16th, 2025
- GT Biopharma Appoints New Member to its Board of Directors - June 16th, 2025
- Connect Biopharma Presents Data Supporting Rademikibart at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress - June 16th, 2025
- PolTREG Establishes U.S. Subsidiary Immuthera to Advance International Development Strategy - June 16th, 2025
- Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple... - June 16th, 2025
- Sunset Social Club Opens as West Hollywood’s First Luxury Cannabis Lounge for Members Only - June 16th, 2025
- IPSEN - Buy-back programme - Art 5 of MAR - Week 23 - 2025 - June 16th, 2025
- 23andMe Reaches Agreement for Sale of Business to TTAM Research Institute Following Final Round of Bidding in Court-Approved Sale Process - June 16th, 2025
- Vaxart Announces Preliminary Results of Annual Meeting of Stockholders - June 16th, 2025
- Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at... - June 16th, 2025
- Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria - June 16th, 2025
- Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R)... - June 16th, 2025
- [Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys™ gene therapy for Duchenne muscular dystrophy in... - June 16th, 2025
- Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema... - June 16th, 2025
- Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor - June 16th, 2025
- Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with... - June 16th, 2025
- Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with... - June 16th, 2025
- Roche to advance prasinezumab into Phase III development for early-stage Parkinson's disease - June 16th, 2025
- EHA 2025 | Multiple Studies Report Encouraging Data of Olverembatinib in Ph+ ALL - June 16th, 2025
- Rapport Therapeutics Hosts Investor and Analyst Day; Provides Corporate Updates - June 3rd, 2025
- Abivax Presents First Quarter 2025 Financial Results - June 3rd, 2025
- Cronos Group Inc. to Speak at the TD Cowen 9th Annual Future of the Consumer Conference - June 3rd, 2025
- Cardiff Oncology Announces Positive Data from Investigator-Initiated Trial of Onvansertib in Combination with Paclitaxel in Metastatic Triple-Negative... - June 3rd, 2025
- Ardelyx Appoints Mike Kelliher Chief Business Officer and James P. Brady Chief Human Resources Officer - June 3rd, 2025
- Vaxart Announces Adjournment of Annual Meeting of Stockholders - June 3rd, 2025
- Sernova Appoints Jonathan Rigby as Interim Chair - June 3rd, 2025
- Neuronetics Set to Join Russell 2000® and Russell 3000® Indexes - June 3rd, 2025
- Harvard Bioscience Appoints John Duke to Board of Directors - June 3rd, 2025
- Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 3rd, 2025
- Quest PharmaTech Provides Corporate Update - June 3rd, 2025
- Kura Oncology and Kyowa Kirin Report Positive Pivotal Ziftomenib Monotherapy Data at 2025 ASCO Annual Meeting - June 3rd, 2025
- Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders - June 3rd, 2025
- Nxera Pharma to Receive US$15 Million from Neurocrine Biosciences Following Dosing of First Patient in Phase 3 Trial of NBI-1117568 - June 3rd, 2025
- Live from ASCO 2025 | Ascentage Pharma Presents Clinical Data on Bcl-2 Inhibitor Lisaftoclax in Venetoclax-Refractory Patients in Oral Report - June 3rd, 2025
- Live from ASCO 2025 | Ascentage Pharma Releases Promising Clinical Data on Alrizomadlin Monotherapy and Combinations in Solid Tumors - June 3rd, 2025
- argenx to Present at Goldman Sachs 46th Annual Global Healthcare Conference - June 3rd, 2025
- Press Release: Rilzabrutinib granted orphan drug designation in the US for sickle cell disease - June 3rd, 2025
- Roche’s Tecentriq combined with lurbinectedin shows significant survival benefit in extensive-stage small cell lung cancer - June 3rd, 2025
- Addex Convenes Annual General Meeting 2025 - June 3rd, 2025
- Crinetics Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2025 - May 26th, 2025
- Allogene Therapeutics Announces Participation in Upcoming Investor Conferences - May 26th, 2025
- IMUNON Announces 2025 ASCO Annual Meeting Oral Presentation Highlighting Unprecedented Survival Data from Phase 2 Trial of IMNN-001 in Treatment of... - May 26th, 2025
- Evaxion to announce business update and first quarter 2025 financial results on May 27, 2025 - May 26th, 2025
- Syncromune® Inc. Announces Publication of Abstract on SYNC-T® Therapy SV-102 Phase 1 Data for Metastatic Prostate Cancer at ASCO 2025 Annual Meeting - May 26th, 2025
- Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2 - May 26th, 2025
- CHMP recommends EU approval of Roche’s Itovebi for PIK3CA-mutated, ER-positive, HER2-negative, advanced breast cancer - May 26th, 2025
- MediPharm Labs Cautions Shareholders about Dissident Nominees’ Governance Failures at Check-Cap Ltd. - May 26th, 2025
- Boundless Bio Announces Portfolio Prioritization and Runway Extension - May 26th, 2025
- Tevogen Bio Plans to Expand Specialty Care Pipeline to Include Patients 65+, Building on Previous Forecast of Nearly $1 Billion in Launch-Year;... - May 26th, 2025
- AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711 - May 26th, 2025
- PMV Pharmaceuticals to Participate at Upcoming Investor Conferences - May 26th, 2025
- Plus Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q - May 26th, 2025
- Zhengye Biotechnology Holding Limited Receives NASDAQ Notice Related to Late Filing of Form 20-F - May 26th, 2025
- IMUNON Announces Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules - May 26th, 2025
- Polyrizon Announces Receipt of Nasdaq Delisting Notice - May 26th, 2025
- Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant... - May 26th, 2025
- ZLNA – Issuance of shares through set-off of option exercise fee - May 26th, 2025
- Guerbet : Changes in the composition of the Guerbet board of directors. - May 26th, 2025
- Chair of Sernova Biotherapeutics Resigns - May 26th, 2025
- Vaxart Approves Resolutions to Narrow Proposed Reverse Split Range and Proposes Reducing Authorized Shares at Future Stockholder Meeting - May 18th, 2025
- Spectral Medical to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference - May 18th, 2025
- Replimune Announces Dates for Fiscal Fourth Quarter and Year End 2025 Financial Results and Upcoming Investor Day - May 18th, 2025
- Windtree Therapeutics Reports First Quarter 2025 Financial Results and Provides Key Business Updates - May 18th, 2025
- Vivex Biologics, Inc. Executive Chair Nominated for Ernst & Young LLP Entrepreneur of the Year® 2025 Florida Award - May 18th, 2025
- PharmaTher Announces FDA Extends Review Period for Ketamine; New Approval Goal Date August 9, 2025 - May 18th, 2025
- Mainz Biomed Announces Interim Read Out For Its eAArly DETECT 2 Clinical Study - May 18th, 2025
- Medicines for Poland: Europe Faces a Critical Choice on Medicines and Market Reform - May 18th, 2025
- Conduit Pharmaceuticals Inc. Announces Reverse Stock Split - May 18th, 2025
- BON Announces The Launch Of Its Postbiotic Hypoglycemic Patented Ingredient Product Series And Its Cooperation Agreement - May 18th, 2025
- Transactions of Managers and Closely Associated Persons - May 18th, 2025
- GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase - May 18th, 2025
- Scilex Holding Company Presented Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the... - May 18th, 2025
- TestoPrime Reviews Side Effects (INVESTIGATED) Is This Testosterone Booster Safe? (Ingredients, Results & Where to Buy) - May 18th, 2025
- BlueSphere Bio Appoints Alan Korman, Ph.D. as Chief Scientific Officer - May 18th, 2025
- 75th Annual Regeneron International Science and Engineering Fair Awards Teen Scientists from Around the World More Than $9 Million in 2025 Competition - May 18th, 2025
- Alvotech Announces the Outcome of the Offering in Connection with the Company’s Listing on Nasdaq Stockholm - May 18th, 2025
- Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference - May 18th, 2025
- Tessera Therapeutics Features New Preclinical Data Demonstrating Progress Across its In Vivo Gene Writing™ Programs and Delivery Platform at the... - May 18th, 2025
- Tectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF... - May 18th, 2025
